BCL2 and idiopathic pulmonary fibrosis: And DQ, which targets BCL-2 family members and HIF-1α, PI3-kinase, and p21-related anti-apoptotic pathways, effectively reduces physical impairment in people with idiopathic pulmonary fibrosis (IPF).